CUMULATIVE INDEX 2000

Volume 18

February	CARDIAC PACING, pages 1–242
May	VENTRICULAR ARRHYTHMIAS, pages 243–408
August	DIASTOLIC FUNCTION AND DYSFUNCTION, pages 409–673
November	TRANSESOPHAGEAL ECHOCARDIOGRAPHY, pages 675–910

Note: Page numbers of article titles are in **boldface** type.

α-adrenergic blockade, for diastolic failure, 595
Amyloidosis, 502, 503
  senile cardiac, 598
Anastomosis, Glenn, transesophageal echocardiography for, 889
Aneurysm, of coronary artery, transesophageal echocardiography in evaluation of, 836 837
Angiosarcoma, transesophageal echocardiography in detection of, 855
Angiotensin-converting enzyme (ACE) inhibitors, for diastolic failure, 593, 594
  in the elderly, 609, 610
Angiotensin-II receptor antagonists (ATA), for diastolic failure, in the elderly, 610, 611
Ankylosing spondylitis, aortic disease in, transesophageal echocardiography of, 721, 722
Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, 341, 342
Aorta, age-related diameter increase in, 599
  coarctation of, diastolic dysfunction in, 492, 493
    transesophageal echocardiography for, 879
Aortic dissection, **807–816**
  complications of, detection of, 808, 809
  congenital heart diseases predisposing to, 807
  diagnostic strategy and pitfalls in, 809, 810
  epidemiology, pathology and pathophysiology of, 807, 808
  intramural hematoma and, 815
  transesophageal echocardiography in, 808–816
    diagnostic accuracy of, 810, 812, 814, 815
    for follow-up, 815, 816
    of ascending aorta and arch, 810–812
    of descending aorta, 810, 813
Aortic regurgitation, transesophageal echocardiography in, 720, 721
Aortic stenosis, subvalvular, discrete, transesophageal echocardiography for, 878
  transesophageal echocardiography in, 718–720
    and study of flow dependence, 720
    for determination of severity of, 718–720
Aortic valve, bicuspid, transesophageal echocardiography for, 876–878
    transesophageal echocardiography of, 712, 713
  congenital abnormalities of, transesophageal echocardiography of, 712, 713
  endocarditis in, transesophageal echocardiography of, 713–717
  prosthetic, transesophageal echocardiography in, 761–763
  quadricuspid, 713
  transesophageal echocardiography of, multiplane examination of, 711, 712
  tricuspid, malformed, transesophageal echocardiography of, 713
  unicuspid, 713
Aortic valve disease, anorexigenic, transesophageal echocardiography in, 722
  carcinoid, transesophageal echocardiography in, 722
  in inflammatory connective tissue diseases, transesophageal echocardiography of, 721, 722
Arrhythmia, termination of, Valsalva maneuver in, 647, 648
  ventricular. See *Ventricular arrhythmias.*
Arthritis, rheumatoid. See *Rheumatoid arthritis.*
Asystole, mechanical stimulation for, 645, 646
Atrial fibrillation, diastolic dysfunction in, treatment of, 592
  initiation of, factors contributing to, 25, 26
  left atrial appendage stunning and, and postcardioversion stunning, 822
    appendage contractile function in, 821, 822
    spontaneous echocardiographic contrast in, 821
    transesophageal echocardiography in, 821, 822
  mechanisms of, 25
  multisite atrial pacing for, 32, 33
  new-onset, transesophageal echocardiography in, 826, 827
  pacing studies of, ideal study outcome event in, 33, 34
  pacing therapies to terminate, 33
  pacing to prevent, **25–36**
    mechanisms of, 26–28
  prevention of, atrioventricular node ablation for, appropriate pacing modality after, 32
    single-site right atrial pacing in, 31, 32
  single-site right atrial pacing for, 28–31
  termination of, preventive therapies after, 33
  transesophageal echocardiography in, **819–831**
    early feasibility studies of, 820, 821
    follow-up for patients in whom a clot is identified, 825, 826

Atrial fibrillation *(Continued)*
for predicting short- and long-term success of cardioversion, 826
general guidelines for, 828
in guided cardioversion using short-term anticoagulation, 822, 823
in maintenance of sinus rhythm, 823, 824
in stratification of thromboembolic risk, 827, 828
newer developments in, 825
versus conventional cardioversion, 823–825
Atrial flutter, transesophageal echocardiography in, 828
Atrial sensing, in management of atrial tachyarrhythmias, 40–42
Atrial septal defects, transesophageal echocardiography in, 869, 870
Atrioventricular delay, 57, 58
Atrioventricular synchrony, 56
Atrium, contraction of, unresolved problems of diastole and, 658–660
in diastolic function, 426, 427
as booster pump, 427
as reservoir, 426, 427
left, normal anatomy of, 851, 852
right, normal anatomy of, 849–851

Baroreflex sensitivity, in risk assessment for ventricular arrhythmias, 252, 253
β Blocker Strategy Plus Implantable Cardioverter-Defibrillators (BEST + ICD) Trial, 354, 355
β blockers, for diastolic failure, 593–595
in the elderly, 609

Calcium, handling of, biophysical mechanisms for, 443, 444
myofilament sensitivity to, shifts in, 448
relationship of with force, dynamic, 444, 445
removal of, relaxation rate limiting, 445–447
sequestration of, in relaxation, 443–448
Calcium channel antagonists, for diastolic failure, 595
in the elderly, 609
Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT), 346–348
Canadian Implantable Defibrillator Study (CIDS), 342, 343
Canadian Trial of Physiologic Pacing, 16
Cardiac Arrest in Seattle: Conventional versus Amiodarone Drug Evaluation (CASCADE) study, 337, 339–341
Cardiac Arrest Study Hamburg (CASH), 343
Cardiac cycle, atrial contraction in, 658–660
diastasis in, 658
isovolumic contraction in, rapid and slow ejection and, 660–662
isovolumic relaxation in, 653–655
left ventricle rapid filling in, 655–658
Cardiac death, sudden, primary prevention of, 257, 258
Cardiac magnetic resonance imaging, for diastole assessment, 557–563
cine imaging in, 558
myocardial tagging in, 559–562
phase contrast imaging in, 558–560
spectroscopy in, 562, 563
noninvasive modalities of, **557–570**
Cardiac pacing leads, **95–112**
Accufix, 107–109
connectors in, 95
coradial bipolar, 105, 106
effect of on energy consumption, 101, 102
epicardial, steroid-eluting, 100
fixation mechanisms of, 97–99
for biventricular pacing, 106, 107
high impedance, 102–105
insulators in, 95–97
single-pass VDD, 106
steroid, 99, 100
uniform code for, 97
Cardiac tamponade, diastolic failure in, 507
Cardiac tumor(s), primary, benign, 855–857
malignant, 855
transesophageal echocardiography in detection of, 854–857
secondary, transesophageal echocardiography in detection of, 853, 854
transesophageal echocardiography in dectection of, 852–858
Cardiomyocyte, electrophysiology of, diastolic stretch and, 641, 642
Cardiomyopathy, diastolic dysfunction in, magnetic resonance imaging analysis of, 565
hypertrophic, left ventricular diastolic dysfunction in, 497, 498
left ventricular outflow tract obstruction in, 67, 68
pacing in, **55–66, 67–79**
clinical experience of, 70–75
historical perspectives on, 67
recommendations for, 75–77
therapeutic reduction of, left ventricular outflow tract obstruction in, 68–70
Cardiovascular function, age-related changes in, 597–606
anatomic, 598, 599
in cardiac structure, 598, 599
in myocardial composition, 598
assessment of, invasive modalities in, **571–586**
noninvasive modalities in, **557–570.** See also *Cardiac magnetic resonance imaging.*
in the elderly, exercise and, 605, 606
invasive measurement of, chamber relaxation in, 572–577
chamber stiffness in, pressure-volume curve in, 577–583. See also *Pressure-volume (PV) curve.*
definition of isovolumic decay waveform in, and mathematical analysis, 572–577
features in, 571, 572
resting, age-related effect on, 599–605
Cardioverter-defibrillator, implantable. See *Implantable cardioverter-defibrillator.*
Chadwick and Brun model of diastole, 461, 465, 468
Chamber size, age-related increase in, 599
Chronotropic assessment, exercise testing for, 169, 170
Chronotropic incompetence, 158–160
Chronotropic response, 157
quantitation of, 170–172
use of pacemaker diagnostics to improve, 168, 169
Cine imaging, gradient echo, of ventricular volume and mass, 558
Coarctation of the aorta, diastolic dysfunction in, 492, 493
Collagen, in cardio reparation, 441
in cardioprotection, 439, 440
myocardial, and interstitial space, 435–438
and tissue mechanics, 437, 438
in regression of fibrosis, 441
infarct scar tissue and, 438, 439
turnover of, 439, 440
Color kinesis, 694, 695

Color M-mode (CMM) Doppler echocardiography, fluid dynamics and, 532, 533
for flow velocity, 528–532
in mitral annulus motion measurement, 427
in transmitral pressure-flow relation study, 427
myocardial tissue velocity in, 529
of myocardial strain, 533
technique of, 532
transthoracic, 530
with pulsed wave, in flow velocity study, 531, 532
Congenital heart disease, aortic stenosis in, 491, 492
coarctation of the aorta as, 492, 493
diastolic dysfunction in, **491–499**
magnetic resonance imaging velocity maps of, 565
Fontan procedure in, 496
hypertrophic cardiomyopathy as, 497, 498
left ventricular diastolic function in, and outflow obstruction, 491, 492
myotonic dystrophy as, 496, 497
of adults, transesophageal echocardiography in, **861–892**
tetralogy of Fallot as, 493–495
univentricular heart as, 494–496
Congestive heart failure, and atrial fibrillation, pacing for patients with, 62, 63
following infective endocarditis, transesophageal echocardiography in, 784
left ventricular dysfunction in, 514, 515
pacing for, **55–66**
effect of on mortality, 63
for hemodynamic indications, 56
for standard bradycardia indications, 55, 56
left ventricular stimulation in, 60–62
right ventricular stimulation site in, 58–60
Connective tissue, and the heart, **435–442**
myocardial, aging and, 598
Connective tissue disease(s), inflammatory, cardiac disease in, transesophageal echocardiography in, 721, 722
Contractile filaments, in heart failure, 454, 455
in stunned myocardium, 454
Coronary arteries, aneurysm of, transesophageal echocardiography in evaluation of, 836, 837
anomalies of, transesophageal echocardiography in evaluation of, 834–837
fistula of, transesophageal echocardiography in evaluation of, 836
stenosis of, transesophageal echocardiography in detection of, 837–839
transesophageal echocardiography in evaluation of, **833–848**
technical aspects of, 833, 834
Coronary Artery Bypass Graft Patch Trial, 350, 351
Coronary artery disease, diastolic failure in, treatment of, 591
Coronary flow, assessment of, using transesophageal echocardiography, 839–843
Coronary flow reserve, assessment of, using transesophageal echocardiography, 839–843
Critical care patient, transesophageal echocardiography in, **789–805**
Cyst(s), echinococcal, transesophageal echocardiography in detection of, 857
pericardial, transesophageal echocardiography in detection of, 857

Defibrillation, by implantable cardioverter-defibrillators, 379–383
Defibrillators in Acute Myocardial Infarction Trial (DINAMIT), 354
Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Trial (DEFINITE), 354
Depolarization, cardiac, diastolic stretch in, 637
Diabetes mellitus, diastolic dysfunction in, treatment of, 591, 592
Diastasis, unresolved problems of diastole and, 658
Diastole, computer modeling of, **459–487**
conceptual issue in, 459
mathematical approaches to, 459, 460
practical issues in, 459, 460
technical advancements and, 460, 461
historical perspective on, 514–516
cardiac catheterization and, 514
echocardiography and, 515
Frank-Starling mechanism and, 514
linear models of, applications of, with model-based image processing, 481, 482
determination of parameters of, from Doppler image, 477–479
parametrized diastolic filling formalism in, 471, 477
physiologic meaning of, 471, 477, 478
patient studies of, 479, 482–484
ventricular diastolic impedance, as potential index of global diastolic function, 484, 485
mechanical, definition of, 637
modeling of, **459–487**
nonlinear models of, chronology of, 461, 462
hemodynamics and, 464–467
of Chadwick and Brun, 461, 465–468
of Meisner, 462–465
of Sun, 461, 470, 471, 473–476
of Thomas, 461, 468–470
suction pump paradigm and model-based image processing, 461, 462
physiology and pathophysiology of, magnetic resonance imaging of, 563–565
unsolved problems in, **653–667**
Diastolic dysfunction, invasive measurement of, definition of isovolumic decay waveform in, relaxation analysis of, 577, 578
Diastolic failure. See also *Heart failure, diastolic.*
β-adrenergic responsiveness in, augmentation of, 627–630
gene transfer approaches to, 627–630
overexpression of adenyl cyclase in, 630
overexpression of β-ARK and β-ARK inhibitor in, 628, 629
overexpression of β-1-adrenergic receptors in, 629, 630
overexpression of β-2 receptor in, 628
overexpression of Gs-α in, 629
β-adrenergic stimulation in, decreased response to, 626, 627
desensitization mechanisms in, 627
molecular aspects in, 626, 627
candidate gene therapy targets in, 630–632
contributing factors in, 626, 627
etiology of, 589
excitation-contraction coupling in, 621, 622
in the elderly, definition of, 606
epidemiology of, 606
hypertension and, 608, 611
neurohormonal activation in, 607, 608
nonpharmacologic treatment of, 611, 612
pathophysiology of, 606–608
pharmacologic therapy for, 608–612
prognosis of, 608
molecular aspects and gene therapy for, **627–635**

Diastolic failure *(Continued)*
muscle relaxation and molecular regulation of, 622–625
phospholamban in, 622, 624
SERCA2a in, 623, 624
transgenic and gene transfer characterization of, 623
troponins in, 624, 625
pathophysiology of, 589, 590
treatment of, **589–596**
ACE inhibitors in, 594
avoidance of volume status extremes in, 592
β blockade in, 594, 595, 609
digoxin in, 595, 596
diuretics in, 593, 594
drug groups for, 593–595
effective, 592
facilitation of diastolic filling time in, 592, 593
goals of, 590–593
in the elderly, 608–612
reversal of ventricular hypertrophy in, 593
underlying disease in, 591, 592
vasodilators in, 595
Diastolic function, atrium in, 426, 427
clinical evaluation of, 563–565
ventricular filling in, 563
computer models of, 427, 428
electrophysiology and, **636–651**
physiology of, **411–433**
diastolic suction and, 422–425
pressure gradient and, 416–422
real-time imaging of, 566, 567
transmitral pressure-flow relations and, 412–416, 431–433
Diastolic stretch, and cardiac nonmyocytes, 642, 643
and cardiomyocyte electrophysiology, 641, 642
and pacemaker electrophysiology, 639–641
chronotropic response of heart in, 643, 644
during sustained mechanical stimulation, 645
during transient mechanical stimulation, 644, 645
pacemaker cells in, 639–641
pathology of, 644, 645
physiology of, 643, 644
respiratory sinus arrhythmia and, 644
stretch-activated ion channels in, 637–639
therapeutic potential of, 645–647
Diastolic suction, definitions of, 422, 423
isovolumic relaxation and, 423, 424
role of in diastolic function, 422–425
Diffusion coefficient mapping, magnetic resonance imaging of, 567, 568
Digoxin, for diastolic failure, 595, 596
in the elderly, 610
Diuretics, for diastolic failure, 593, 594
Doppler echocardiography, color M-mode, for flow propagation velocity, 528–532
of E- and A-waves, model-based image processing of, 533, 534
of left ventricle filling patterns, M-mode, 522
pulsed-wave, 521–523
two-dimensional, 522
of left ventricular diastolic function, **513–545**
tissue imaging in, 525–527
Ductus arteriosus, patent, transesophageal echocardiography for, 886

Ebstein's malformation of the tricuspid valve, transesophageal echocardiography for, 878
transesophageal echocardiography in, 748
Echo-Doppler evaluation. See *Doppler echocardiography.*
Echocardiography, contrast, 695
transesophageal. See *Transesophageal echocardiography.*
Ejection fraction, left ventricular, assessment of, 246, 247
Elderly, diastolic dysfunction in, **597–617**
pathophysiology of, 606–608
treatment of, 608–612
Electrocardiogram, signal-averaged, in risk assessment for ventricular arrhythmias, 253, 254
Electron beam tomography (EBT), cardiac diastolic function quantification by, **547–556**
in hypertrophic cardiomyopathy, 555
in myocardial infarction, 553, 554
in normal subjects, 552, 553
in valvular heart disease, 554, 555
methods of, 551, 552
computed tomography and, development of, 548, 549
in cardiovascular imaging, limitations of, 551
strengths of, 550, 551
technical aspects of, 549, 550
Embolization, following infective endocarditis, transesophageal echocardiography in, 784, 785
Endocarditis, infective, complications of, detection and management of, 783–785
congestive heart failure and, transesophageal echocardiography in, 784
diagnosis of, 776–783
differential, using echocardiographic findings, 782, 783
Duke criteria for, 776–779
transesophageal echocardiography in, 779–782
transthoracic echocardiography in, 779
embolization following, transesophageal echocardiography in, 784, 785
follow-up in, 785
Löffler's, heart failure in, 503, 504
of aortic valve, complications of, 715–717
transesophageal echocardiography in, 713–717
organisms responsible for, 774, 775
pathogenesis of, 773–775
pericarditis in, 785
perivalvular extension of, transesophageal echocardiography in detection of, 783, 784
transesophageal echocardiography in, **773–787**
intraoperative, 785
underlying cardiac conditions and, 774
Eosinophilia, heart failure in, 503, 504
European Myocardial Infarct Amiodarone Trial (EMIAT), 345, 346
Exercise, diastolic function and, in the elderly, 605, 606

Fibrillation, atrial. See *Atrial fibrillation.*
Fibroelastoma, papillary, transesophageal echocardiography and, 717, 718
transesophageal echocardiography in detection of, 856
Fibroma, cardiac, transesophageal echocardiography in detection of, 857
Fistula, of coronary artery, transesophageal echocardiography in evaluation of, 836
Fontan procedure, in congenital heart disease, 496
transesophageal echocardiography in, 887, 888

Glenn anastomosis, transesophageal echocardiography for, 887

Group for the Study of Survival in Heart Failure in Argentina (GESICA) trial, 343–345

Heart disease, acquired, magnetic resonance imaging velocity maps of, 565, 566
congenital. See *Congenital heart disease.*
Heart failure, contractile filaments in, 454, 455
diastolic, **501–509**
endomyocardial disorders in, 503, 504
in amyloidosis, 502, 503
in constrictive pericarditis, 505, 506
in elderly patient, 483
in hemachromatosis, 504, 505
in myocardial disorders, 501–505
in pericardial disorders, 505–507
in pericardial effusion with cardiac compression, 507
in pericarditis, 505–507
in restrictive cardiomyopathy, 501, 502
idiopathic, 503
Hemachromatosis, heart failure in, 504, 505
Hematoma, intramural, and aortic dissection, 815
Hydralazine-isosorbide dinitrate, for diastolic failure, 595
Hypertension, aortic dissection and, 807
diastolic dysfunction in, magnetic resonance imaging analysis of, 565, 566
treatment of, 591
diastolic filling patterns in, 482, 483
in diastolic failure, 608
Hypertrophic cardiomyopathy (HCM), diastolic dysfunction in, 497, 498
diastolic function in, electron beam tomography quantification of, 555
pressure-volume curves in, conductance catheter measurement of, 579, 580

Impedance, ventricular diastolic, as index of global diastolic function, 484, 485
ventriculoarterial systolic, 484
Implantable cardioverter-defibrillator, complications of, 383
defibrillation by, 379–383
for treatment of ventricular tachyarrhythmias, 357
ancillary antiarrhythmic drug therapy for, 367, 368
in the new millennium, **375–389**
indications for, 375, 376
future directions of, 383–385
pacing capabilities of, 378, 379
rate sensing by, 376–378
Intracardiac anatomy and artifacts, normal, 851–854
Isovolumic contraction, with rapid and slow ejection, unresolved problems of diastole and, 653–655
Isovolumic relaxation, of left ventricle, 516–518
age-related delay in, 604, 605
rate of, 417, 418, 422, 423
unresolved problems of diastole and, 653–655
Isovolumic relaxation time (IVRT), in echo-Doppler evaluation, 536
of left ventricle filling, 518

Lambl's excrescences, 717, 782, 783
transesophageal echocardiography in detection of, 856
Left ventricle. See also *Ventricle.*
chamber properties of, and pressure gradient, 416–422
deformation not relative to equilibrium volume, 419, 420
direct versus indirect determinants of, 421, 422
isovolumic relaxation rate and, 417, 418
myocardial viscoelasticity and, 420
passive pressure-volume relation in, 418–420
relaxation rate-filling pressure relation in, 422, 423
diastolic dysfunction of, 514–516
diastolic properties of, operating chamber compliance and, 517, 518
relaxation as, 516–518
transmitral pressure gradient and, 516, 517
filling patterns of, 518–521
abnormal mitral, 520, 521
change in cardiac loading conditions and, 524, 525
changes in with aging, 519, 520
M-mode and two-dimensional echocardiography of, 522
mitral flow velocity variables in, 518, 519
mitral-to-pulmonary venous A-wave relation and, 524, 525
natural history of, 521
pulmonary venous flow velocity and, 521–523
pulsed-wave Doppler echocardiography of, 521–523
tricuspid flow velocity and echocardiography of, 522, 524
filling pressures of, color M-mode Doppler flow velocity and, 531, 532
relaxation rate and, 422, 423
isovolumic relaxation time of, 518
normal anatomy of, 852
Left ventricular diastolic filling, Doppler data for, in the elderly, 600
normal pattern in, 601–603
in the elderly, 599
delayed isovolumic relaxation in, 604, 605
noninvasive assessment of, 599, 600
patterns of, 603, 604
pseudonormalization of, 604
rapid, unresolved problems of diastole and, 655–658
restrictive early filling in, 604, 605
Left ventricular diastolic function, and outflow obstruction, 491, 492
echo-Doppler evaluation of, **513–545**
application of in patient management, 535, 536
isovolumic relaxation time and, 536
mitral A-wave in, duration of, 538–540
mitral deceleration time in, 537, 538
mitral E-wave velocity in, peak, 537
mitral flow velocity in, 538, 539, 541
mitral flow velocity integral and, 536
technique of, 534, 535
Left ventricular outflow tract, discrete subvalvular obstruction of, transesophageal echocardiography in, 724, 725
dynamic subvalvular obstruction of, transesophageal echocardiography in, 725, 726
obstructions of, transesophageal echocardiography for, 878–881
transesophageal echocardiography of, 724–726
multiplane examination in, 724
Lipoma, cardiac, transesophageal echocardiography in detection of, 856
Long QT syndrome, **309–325**
clinical genetics in, 314, 315
clinical manifestations of, 315
electrocardiogram manifestations of, 316–319
genotypes of, relative frequency of, 314
HERG and MiRP1 in, 312, 313

Long QT syndrome (Continued)
KvLQT1 and MinK in, 311, 312
LQT4 in, 314
management of, 321, 322
molecular genetics of, 309–314
pathophysiology of, 319–321
SCN5A in, 313, 314
Lupus erythematosus, systemic, aortic valve disease in, transesophageal echocardiography of, 721
Lymphosarcoma, cardiac, primary, transesophageal echocardiography in detection of, 855

Magnetic resonance imaging, of physiology and *pathophysiology of diastole, 563–565*
Magnetic resonance imaging velocity maps, of diastolic dysfunction, in acquired heart disease, 565, 566 in congenital heart disease, 565
of diastolic function, clinical evaluation of, 563–565
Magnetic resonance spectroscopy (MRS), purpose of, 562
Marfan syndrome, aortic dissection and, 807
Meisner model of diastole, applications of, 465
evolution of, 462–465
Mitral annular motion (MAM), tissue Doppler imaging pulsed-wave analysis of, 526–528
Mitral filling velocity, in the elderly, healthy, 601, 602
with manifest cardiovascular disease, 601, 603
Mitral flow velocity patterns, and left ventricular diastolic dysfunction, 518–521
Mitral valve, anatomy of, 731
annular calcification of, transesophageal echocardiography in, 736
congenital abnormalities of, transesophageal echocardiography of, 744
endocarditis of, transesophageal echocardiography in, 743
flail, transesophageal echocardiography in diagnosis of, 740, 741
intraoperative assessment of, by transesophageal echocardiography, 744, 745
paravalvular leak of, transesophageal echocardiography of, 743
prolapse of, transesophageal echocardiography in, 737, 739, 740
prosthetic, transesophageal echocardiography in, 759, 760
regurgitation in, transesophageal echocardiography in, 736–738, 741, 743
rheumatic disease of, transesophageal echocardiography in, 733–736
systolic anterior motion of, transesophageal echocardiography of, 743, 744
transesophageal echocardiography of, standard, 731–733
Model-based image processing (MBIP), of Doppler E- and A-waves, 533, 534
Mortality, in elderly patient with heart failure, parametric diastolic filling model-based image processing in, 483
Multicenter Automatic Defibrillator Implantation Trial (MADIT), 350–352, 355
Multicenter Unsustained Tachycardia Trial (MUSTT), 353, 354
Myocardial infarction, diastolic function in, electron beam tomography quantification of, 553, 554
Myocardial strain, tissue Doppler imaging of, color M-mode, 533
Myocardial tagging, comparison of with magnetic resonance imaging, 560, 561
diastolic dysfunction in, 565–567
evaluation of tagged image in, 562
magnetic resonance imaging sequence in, through cardiac cycle, 561
myocardial motion in, 560
pattern in, 561
tag persistence in, 561
Myocardial velocity gradient, relation of to Doppler E-wave, 483, 484
Myocardium, collagen network in, 435–438
collagen turnover in, and cardioprotection, 439, 440
hypertrophic growth of, 435
infarct scar tissue and, 438, 439
interstitial space of, collagen network in, 435–437
stunned, contractile filaments in, 454
Myocytes, age-related degeneration of, 598
relaxation rate of, calcium uptake and, 447
Myofilaments, and calcium handling, in left ventricular relaxation, **443–457**
sensitivity of, and calcium sequestration during relaxation, 443–448
Myotonic dystrophy (Steinert's disease), diastolic dysfunction in, 496, 497
differences in infant and adult-onset and, 497
Doppler echocardiography in, 497
Myxoma, transesophageal echocardiography in detection of, 855, 856

Osteosarcoma, cardiac, extraskeletal, transesophageal echocardiography in detection of, 855

Pacemaker Atrial Tachycardia (Pac-A-Tach) trial, 15
Pacemaker leads, extraction of, current concepts in, **193–217**
definition of, 193, 194
historical perspective on, 202, 203
in Accufix and Encor brands, 195–197
indications for, 194, 195, 216, 217
migrated, 200, 201
owing to infection, 198, 199
owing to subclavian crush, 201, 202
owing to venous thrombosis, 199, 200
pathology of, 197, 198
patient preparation for, 203, 204
tools for, 204–208
using a weight and pulley, 202
using counter-pressure and counter-traction, 203
using traction, 202
venous insertion site technique for, 208–214
via open heart surgery and limited atriotomy, 202, 203
when multiple leads are present, 199
Pacemaker Selection in the Elderly study, 10, 11
Pacemakers. See also *Pacing.*
automated, advantages of, 188
automatic capture and, 177–181
diagnostics using, 187, 188
disadvantages of, 188–190
function of, **177–191**
implant and follow-up using, 188
mode switching in, 186
optimization of atrioventricular synchrony in, 185, 186
rate responsive pacing in, 184, 185
sensing functions of, 181–184
therapies using, 186, 187

mode switching algorithms of, 44–48
sensor-driven, activity sensors, accelerometers, and minute ventilation sensors in, 164, 165
automation in, 167
dual-sensor, 165–167
exercise and, 160
lower rate programming in, 161, 162
programming of, **157–176**
sensor slope in, 163, 164
sensor threshold in, 160, 161
upper rate programming in, 162, 163
Pacing. See also *Pacemakers.*
by implantable cardioverter-defibrillators, 378, 379
dual-chamber, versus ventricular, 1
electromagnetic interference with, **219–239**
clinical consequences of, 226
daily life sources of, 226–231
damage to generator or electrode-myocardial interface from, 225, 226
from cellular telephones, 226–228
from electric power sources, 230
from electronic antishoplifting devices, 228–230
from metal detectors, 230
from slot machines, 231
in the working environment, 231
knowledge about, 220, 221
medical sources of, 231–237
noise-reversion mode and, 223
pacing inhibition from, 222
power-on reset and, 223–225
rapid or premature pacing triggered by, 222
sources of, classification of, 219, 220
spurious tachyarrhythmia detection and, 222, 223
rate-adaptive, activity sensing in, 121–123
automaticity in, 136–145
autoprogrammability in, 138–143
cardiac contractility in, 128–130
central venous oxygen saturation in, 126, 127
classification of sensors in, *114–116*
closed-loop versus open-loop sensors in, 116–118
components of, 114
dual-sensor, 134–136
historical landmarks of, 113, 114
ideal behavior in, 145–149
ideal, characteristics of, 118–120
innovative physiologic sensors in, 126–131
minute ventilation sensing in, 123–125
peak endocardial acceleration in, 130, 131
principles for integrating sensors in, 133, 134
right ventricular pressure in, 127, 128
semiautomatic programming in, 138
sensor combination in, 131–133
ventricular depolarization gradient in, 130
ventricular paced Q-T interval in, 125, 126
rate-responsive, closed-loop, 172–174
in children, 167, 168
sensor-driven, developments in, **113–155**
to prevent atrial fibrillation, **25–36**
ventricular, potential detrimental effects of, 34
versus dual-chamber, 1
Pacing mode, selection of, clinical trials of, **1–23**
current recommendations for, 1, 2
nonrandomized observations studies of, 4–8
ongoing clinical trials in, 12–18
PASE Study of, 10, 11
prospective randomized studies, 8–12
small crossover studies of, 2–4
Parametrized diastolic filling (PDF) paradigm, 471
parameters of, damping constant, 478, 481
determination of from Doppler image, 477
initial spring displacement in, 477
machine dependence of, 482
physiologic meaning of, 477, 478
spring constant in, 477, 478
Pericardial effusion, diastolic failure in, 507
Pericardiectomy, in constrictive pericarditis, 506
Pericardiotomy, in pericardial effusion with cardiac compression, 507
Pericarditis, constrictive, diastolic failure in, 505–507
echocardiography in, 506
management of, 506
effusive-constrictive, diastolic failure in, 507
Pericardium, age-related changes in, 599
Phase contrast imaging, in phase-shift velocity mapping, 558–560
technical considerations in, 558–560
Phospholamban (PLB), in diastolic regulation, 625
in excitation-contraction coupling, 622
Pressure-volume (PV) curve, diastolic, analysis of, 572, 579–581
influences on, 581–583
measurement of, for intracardiac electrical impedance, 572, 577–579
imaging-based, 577
Prosthetic valve(s), dysfunctional, transesophageal echocardiography in, 763–769
infective endocarditis in, transesophageal echocardiography for, 764–766
mechanical, transesophageal echocardiography in, 755, 756
mechanical failure of, transesophageal echocardiography for, 766–768
paraprosthetic regurgitation in, transesophageal echocardiography for, 768
prosthesis-patient mismatch and, transesophageal echocardiography for, 769
stented bioprostheses, transesophageal echocardiography in, 756, 757
stentless aortic bioprostheses, transesophageal echocardiography in, 757–759
thrombus and pannus formation in, transesophageal echocardiography for, 764
transesophageal echocardiography of, **751–771**
anticipated findings in, 754
constraints and artifacts in, 751–753
Doppler assessment of regurgitation in, 753, 754
Doppler hemodynamics in, 753
implications of prosthesis type for, 755–759
indications for, 754
Pulmonary stenosis, transesophageal echocardiography for, 876
Pulmonary venous flow velocity, pulsed-wave Doppler, in left ventricular filling assessment, 521–523
Pulmonic valve, imaging of, transesophageal echocardiography in, 722–724
infective endocarditis of, transesophageal echocardiography in, 723, 724
prosthetic, transesophageal echocardiography in, 763

QT dispersion, in risk assessment for ventricular arrhythmias, 247, 249, 250
QT interval, in risk assessment for ventricular arrhythmias, 247, 249, 250

Radionuclide angiography, 547, 548
Rate Modulated Pacing and Quality-of-Life Study, 15, 16

Relaxation, ventricular, calcium and, removal of, 445–447
sequestration of, 443–448
crossbridge dissociation in, 449–454
versus calcium sequestration, 449–451
displacement-dependence of, 453, 454
in heart failure, SERCA pump and, 447, 448
isometric, load dependence of, 451, 452
left, delayed, diastolic filling and, 604
echo-Doppler evaluation of, 536
in diastole, 516–518
isovolumic, delayed, 604, 605
load-dependent, crossbridges cooperativity in, 452, 453
Rhabdomyoma, transesophageal echocardiography in detection of, 857
Rhabdomyosarcoma, transesophageal echocardiography in detection of, 855
Rheumatoid arthritis, aortic valve disease in, transesophageal echocardiography for, 721
Right ventricle, double-outlet, transesophageal echocardiography for, 884, 885
normal anatomy of, 852
Right ventricular diastolic function, interpretation of, Doppler analysis of, 541, 542
Right ventricular outflow tract, obstruction of, transesophageal echocardiography in, 724
obstructions of, transesophageal echocardiography for, 874–876

Shunt(s), aortopulmonary, transesophageal echocardiography for, 887
Spondylitis, ankylosing. See *Ankylosing spondylitis.*
Steinert's disease. See *Myotonic dystrophy.*
Stretch-activated ion channels, cell-volume activated, 638, 639
in cardiac depolarization, 637, 638
nonselective, Gadolinium blockade of, 639
potassium selective, 638, 639
sodium selective, 638
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 354
Sun model of diastole, applications of, 470, 471, 473–476
Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure, 345
Survival With Oral D-sotalol (SWORD) study, 348–350
Syncope, vasovagal. See *Vasovagal syncope.*
Systematic Trial of Pacing to Prevent Atrial Fibrillation, 17

T-wave alternans, in risk assessment for ventricular arrhythmias, 250, 251
Tachyarrhythmia/fibrillation, chest thump for, 645–647
intracardiac mechanical stimulation for, 647
treatment of, 592
Tachyarrhythmias, atrial, detection of, 42–44
future of mode switch technology for, 52
management of, in patients with pacemakers, **37–53**
mode switching algorithms in pacing for, 44–48
programming considerations in pacing for, 48–52
Tachycardia, ventricular. See *Ventricular tachycardia.*
Tetralogy of Fallot, diastolic dysfunction in, 493–495
transesophageal echocardiography for, 874–876
Thomas model of diastole, 461, 468–471
applications of, 469
variables in, 468
Thrombus, detection of, with transesophageal echocardiography, 718
Tissue Doppler imaging, 694
color M-mode, 528–532
advantage of, 528, 531
of myocardial strain, 533
technique of, 532
variable of, 531
description of, 525, 526
future applications of, 532, 533
limitation of, 526–528
pulsed-wave, in spectral analysis of mitral annular motion, 526–528
limitation of, 528
Transesophageal echocardiography, and newer echocardiographic modalities, 694, 695
clinical applications of, 675, 676
evolution of, 675, 676
technical, 675
for obstructions of left ventricular outflow tract, 876–879
for obstructions of right ventricular outflow tract, 874–876
hemodynamics derived from, **699–709**
case study of, 707, 708
Doppler flow and, 702–704
historical perspective on, **675–679**
in aortic dissection, 808–816
in atrial fibrillation, **819–831**
in atrial septal defects, 869, 870
in atrioventricular septal defects, 873, 874
in congenital heart disease of adults, **861–892**
anatomic and hemodynamics assessment using, 866, 867
image acquisition in, 863–866
in the catheterization laboratory, 867, 868
indications and contraindications for, 862, 863
intraoperative use of, 868, 869
limitations of, 888
skills needed to perform, 862
technique of, 863
in critical care patient, **789–805**
continuous monitoring issues in, 801, 802
cost-effectiveness of, 802
for aortic dissection, 796, 797
for complications of cardiothoracic surgery, 794, 795
for complications of myocardial infarction, 794, 796
for determining source of cardiac embolus, 799–801
for endocarditis, 797, 798
for evaluation of potential transplant donors, 802
for guidance of central line placement, 802
for suspected pulmonary embolus, 797, 799
for unexplained hypotension, 792
for unexplained hypoxemia, 792, 794
impact of on management of, 802, 803
indications for, 792–801
limitations of, 790, 792
safety issues in, 789, 790
technique of, 789
versus pulmonary artery catheterization, 792, 793
in diastolic function assessment, 693
in evaluation of coronary arteries, **833–848**
in evaluation of infective endocarditis, **773–787**
in evaluation of intracardiac and pericardial masses, **849–860**
in evaluation of mitral and tricuspid valves, **731–750**
in evaluation of prosthetic valves, **751–771**
in evaluation of ventricular function, **681–697**
in left ventricular function assessment, during cardiac surgery, 691, 692

versus pulmonary artery catheterization, 792, 793
load-independent measures in, 690
regional, 690, 691
in right ventricular function assessment, 693
in ventricular function assessment, automated border detection in, 687, 688
common useful views in, 683, 684
estimation of cardiac output in, 688–690
for global systolic function, 684–686
history of, 681, 682
indications for, 682, 683
limitations of, 694
midesophageal four-chamber view in, 684
midesophageal two-chamber view in, 684
noninvasive measurement of dP/dt in, 690
stress testing and, 693, 694
transgastric long-axis view in, 683
transgastric short-axis view in, 683
volume estimates in, 686, 687
in ventricular septal defects, 871–873
investigational, indications for, 676
mitral inflow in, for hemodynamic evaluation, 703, 704
mitral regurgitation in, imaging of, 704, 705
of great veins, 706, 707
for hemodynamic evaluation, 701
of hepatic veins, 707
for hemodynamic evaluation, 701
of interatrial septum, for hemodynamic evaluation, 701
of left atrium, for hemodynamic evaluation, 700
of left ventricle, for hemodynamic evaluation, 699, 700
of pulmonary artery and left ventricular outflow tract, for hemodynamic evaluation, 704
of pulmonary veins, for hemodynamic evaluation, 702, 703
of right atrium, for hemodynamic evaluation, 700, 701
of right ventricle, for hemodynamic evaluation, 700
of the aortic valve, left ventricular outflow tract, and pulmonic valve, **711–729**
primary, indications for, 676
pulmonary regurgitation in, imaging of, 706
secondary, indications for, 676
state of the art of, 677, 678
three-dimensional, 695, **893–910**
clinical applications of, 899–905
current limitations of, 904, 905
cutting planes in, 895
data acquisition techniques in, 894, 895
data processing and rendering in, 895
evolving advances and future directions in, 905
for cardiac masses, 904
image rendering in, 897, 898
imaging of color flow jets with, 898
in aortic dissection, 904
in congenital heart disease, 903, 904
in evaluation of myocardial perfusion abnormalities, 901, 902
in imaging of coronary arteries, 902, 903
in ischemic heart disease, 901
in quantitation of left ventricle volumes and mass, 901
in valvular heart disease, 899–901
of aortic valve, 900, 901
of mitral valve, 899, 900
principles and techniques of, 894–898
therapeutic uses of, 906
training guidelines for performance of, 676, 677
tricuspid regurgitation in, imaging of, 705, 706
Transmitral flow, comparison of nonlinear and linear model predictions for, model-based image processing in, 481, 482
differentiation of hypertensive from normal filling patterns of, 482, 483
Doppler image of, 481
Transmitral flow velocity, pulsed-wave Doppler study of, 515, 516
Transmitral pressure-flow relations, color M-mode Doppler and, 427
in diastolic filling, experimental observations of, 413–416
history of, 413, 414
validation of, 412, 413
Transposition of the great arteries, *d*-variant of, transesophageal echocardiography for, 878–883
l-variant of, transesophageal echocardiography for, 883, 884
congenitally corrected, transesophageal echocardiography for, 883, 884
Tricuspid valve, Ebstein's malformation of, transesophageal echocardiography for, 878
endocarditis in, transesophageal echocardiography of, 746
normal anatomy of, 745
prolapse of, transesophageal echocardiography in, 747, 748
prosthetic, transesophageal echocardiography in, 763
regurgitation in, transesophageal echocardiography in, 746, 747
standard transesophageal echocardiography imaging of, 745, 746
stenosis of, transesophageal echocardiography in, 746
Tropin I, in excitation-contraction coupling, 622
Troponins, characterization of, molecular, 624, 625
transgenic, 625
Truncus arteriosus, transesophageal echocardiography for, 885, 886

United Kingdom Pacing and Cardiovascular Events trial, 17, 18

Valve(s). See under specific types, e.g., *Mitral valve.*
age-related thickness increase in, 599
Valvular disease, diastolic failure in, treatment of, 591
diastolic function in, electron-beam tomography quantification of, 554, 555
Vasodilators, for diastolic failure, 593–595
in the elderly, 610
Vasovagal syncope, assessment and treatment of, 83, 84
health-related quality of life in, 82, 83
impact of, 81–83
mortality of, 82
pacing to prevent, **81–93**
clinical studies of, 86–88
optimal mode in, 89–91
patient selection for, 91
quality of life and cost utility in, 88, 89
rationale for, 84–86
tilt-table testing and, 83, 85, 86
Velocity-encoded cine magnetic resonance (VEC-MR), 559, 560
Ventricle. See also *Left ventricle.*
electron-beam tomography of, for function, 548–555
for size and shape, 548
left, normal anatomy of, 854

Ventricle *(Continued)*
right, normal anatomy of, 854
wall thickness of, age-related changes in, 599
Ventricular arrhythmias, diseases associated with, 244
implantable defibrillator with antiarrhythmic drug therapy for, adverse interactions of, 403
beneficial effects of, 402, 403
effect of drug therapy on device effectiveness in, 403–405
in normal hearts, **265–291**
management of, assessment of ablative therapy for using diagnostic information from the ICD, 399–401
catheter ablation with implantable defibrillator therapy for, 391–401
catheter ablative therapy with implantable cardioverter-defibrillator therapy in, 401
electrophysiologic testing for assessing efficacy of therapy for, 391–393
end points for defining success of catheter ablation for, 394–399
hybrid therapy for, **391–406**
implantable cardioverter-defibrillator risk in, 393, 394
large clinical trials in, **337–356**
pathology of, 243, 244
pathophysiology of, 244, 245
primary prevention trials in, 343–355
risk assessment for, application of noninvasive and invasive tests for, **243–263**
baroreflex sensitivity in, 252, 253
combined testing in, 255–257
electrophysiologic study in, 254, 255
heart-rate variability in, 251, 252
invasive tests in, 254, 255
left ventricular ejection fraction in, 246, 247
noninvasive tests in, 246–254
QT dispersion in, 247, 249, 250
QT interval in, 247, 249, 250
signal-averaged electrocardiogram in, 253, 254
summary, recommendations, and potential future applications in, 258, 259
T-wave alternans in, 250, 251
risk stratification in, designing techniques of, 246
goals of, 245, 246
secondary prevention trials in, 337, 339–343
spontaneous, 247
Ventricular function assessment, transesophageal echocardiography in, **681–697**
Ventricular hypertrophy, treatment of, 593
Ventricular outflow tract. See also *Right ventricular outflow tract* and *Left ventricular outflow tract.*
imaging of, transesophageal echocardiography in, 722–724
Ventricular septal defects, transesophageal echocardiography in, 871–873
Ventricular tachyarrhythmias, sustained, ablation/isolation of the arrhythmogenic substrate in, 361
amiodarone therapy for, empiric, 360
ancillary antiarrhythmic drug therapy for patients with implantable cardioverter-defibrillators in, 367, 368
β-blocker therapy for, empiric, 360, 361
clarification of treatment goals in, 362
comparison of treatment approaches in, 362–364
drug therapy for, **357–373**
future of antiarrhythmic therapy for, 368, 369
implantable cardioverter-defibrillator therapy for, 361, 362
individualized antiarrhythmic drug therapy for, 359, 360
primary antiarrhythmic drug therapy for, 366, 367
revascularization therapy for, 361
review of the problem of, 358, 359
selection of primary therapy for, 365, 366
standard antiarrhythmic drug therapy for, empiric, 359
treatment approaches for, 359–362
Ventricular tachycardia, adenosine-sensitive, 265–280
clinical characteristics of, 265–267
differential diagnosis of, 278–280
electrophysiologic diagnosis of, 272, 273
mechanism of, 267–270
noninvasive diagnosis of, 270–272
treatment of, 273–278
variants of, 278
automatic, 286, 287
intrafascicular, verapamil-sensitive, 280–286
anatomic substrate in, 280–282
clinical characteristics of, 280
mechanism of, 282–286
nonsustained, **327–336**
in patients with coronary artery disease, 332, 334
in patients with dilated cardiomyopathy, 331, 332
in patients with hypertrophic cardiomyopathy, 330, 331
in patients with mitral valve prolapse, 329, 330
in persons without apparent structural heart disease, 327–329
post-infarct, antiarrhythmic drugs for, 297, 298
catheter ablation for, 298–303
changing epidemiology of, 294, 295
electrophysiology study in, 296, 297
evaluation of, 295–297
management of, **293–307**
management options in, 297–304
pathophysiology of, 293, 294
search for reversible causes of, 295, 296
surgical ablation for, 303, 304
postinfarct, ablative therapy for, 298–304
propranolol-sensitive, 286, 287
Volume status, in diastolic failure, 592

Wall motion, abnormal, implications of, 495
diastole in, 564, 565